Skip to main content
Egyptian Liver Journal
Download PDF
  • Original Research Article
  • Open access
  • Published:

Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)

Egyptian Liver Journal volume 13, Article number: 49 (2023) Cite this article

Abstract

Background

Regression of fibrosis and improvement of portal hemodynamics after achievement of sustained viral response (SVR) in patients with chronic hepatitis C (HCV) is a subject of debate in different studies. Some studies reported improvement in the degree of fibrosis, while others did not find significant changes.

Objective

We aimed to evaluate changes in liver fibrosis, portal hemodynamics and clinical outcomes in patients with chronic HCV-related liver cirrhosis after the achievement of SVR with direct-acting antiviral drugs (DAAs).

Patients and methods

In our prospective longitudinal study, a total of 100 patients with chronic HCV infection-related liver cirrhosis were recruited, received DAAs, and completed the follow-up period. Clinical evaluation for assessment of liver disease severity using MELD and Child–Pugh class and scores were done. A noninvasive assessment of liver fibrosis using serum biomarkers (APRI index & FIB4 score) and share wave elastography (SWE) was done. Portal hemodynamic evaluation using Doppler ultrasound was done. All were done at baseline and 3 and 12 months after the end of therapy.

Results

A significant reduction in the degree of fibrosis was observed. Share wave elastography (SWE) readings showed 19.79% and 30.45% reduction 3 and 12 months after the end of therapy respectively (P < 0.001). Regarding the FIB4 score, the percentage of score reduction was 19.8% and 26.46% 3 and 12 months after the end of therapy, respectively (P < 0.01). APRI scores showed 22.6% and 41.09% reduction 3 and 12 months after the end of therapy respectively (P < 0.001). Significant improvement in Child–Pugh scores 3 and 12 months after the end of treatment was observed. Doppler ultrasound showed a significant increase in portal vein flow velocity, a significant decrease in time average mean velocity, and cross-section area 12 months after the end of treatment.

Conclusion

There was a considerable degree of reduction of liver fibrosis, improvement of portal hemodynamics, and Child–Pugh score in cirrhotic HCV patients who achieved SVR after DAAs.

Trial registration

ClinicalTrials.gov, ID: NCT03241823. Registered on 08 May 2017.

Introduction

Before the introduction of direct-acting antiviral drugs (DAAs), there were about 71 million infected patients with hepatitis C virus (HCV) worldwide; of them, 55–85% have had chronic liver disease [1]. It was found that liver cirrhosis complicates 10–30% of patients within 2 decades of infection. Hepatocellular carcinoma was found to develop each year in 1–4% of patients with HCV-related liver cirrhosis [2, 3]. Since 2014, after DAAs’ introduction into the clinical practice, there has been a dramatic improvement in HCV management with a shorter duration of treatment and less adverse effects than interferon-based therapy, with SVR reaching 95% of cases [4]. DAAs (in contrast to interferon-based regimens) can be given to patients with liver cirrhosis.

Despite the recent advances in DAAs, data about its effects on the degree of fibrosis regression is still not enough. Reduction of liver fibrosis scores with its clinical impact on the clinical status of the patients is the optimum aim and hope of treatment with DAAs now [5, 6]. Previous studies noted a reduction in fibrosis using SWE, FIB-4 score, and APRI. This reduction may be due to a reduction in fibrosis or the inhibition of HCV-induced hepatic inflammation and edema in hepatic tissue. This reduction is still not known whether it impacts the clinical status of the patient or not [6,7,8].

To our knowledge, few studies in our locality that assessed the effects of DAAs on the fibrosis degree, portal hemodynamics, and the clinical outcome after achieving SVR. In the current study, we tried to study the effects of DAAs on liver fibrosis, portal hemodynamics, and clinical outcomes.

Patients and methods

In our prospective longitudinal study, one hundred patients with chronic HCV-related liver cirrhosis who attended Al-Rajhi Liver Hospital, Assiut University, were enrolled in our study during the period between December 2018 and December 2021.

Inclusion criteria

Age 18–80 years old and HCV infection-related cirrhosis with Child–Pugh class (A & B).

Exclusion criteria

Child C liver cirrhosis, HCV co-infection with hepatitis B virus or HIV, contraindications to DAAs (pregnancy, lactation, hypersensitivity to one of the drugs in the treatment regimen), causes of chronic liver disease other than HCV, patients with hepatocellular carcinoma, and if the patient refused.

Sample size calculation

We obtained the reference value for the fibrosis stage regression according to poster 777 (in AASLD), 2015 [9]. For accurate calculation of the fibrosis stage, 98 patients would be included to achieve a 95% confidence interval and a width equal to 0.2. We enrolled 116 patients at the start of the study. Sixteen patients were lost for follow-up during the period of the study and 100 patients completed the follow-up period.

All patients were evaluated as regards the following:

Thorough history and clinical examination, abdominal ultrasound, Doppler ultrasound, share wave elastography (SWE), and laboratory investigations were done before therapy, 3 and 12 months after the end of therapy.

The laboratory investigations included HCV Ab, PCR for HCV RNA (quantitative), complete blood count, prothrombin time, INR, liver enzymes (alanine transaminase, aspartate transaminase), serum bilirubin, serum albumin, blood urea, serum creatinine, fasting blood sugar and HbA1c (if the patient is diabetic), HBs Ag, and alpha-fetoprotein.

Non-invasive laboratory fibrosis markers:

  • FIB-4 score = Age (years) × AST (IU/L)/platelet count (109/L) × √ ALT (IU/L) [10]

  • AST/platelet ratio index (APRI) = [AST (IU/L)/AST upper limit of normal (IU/L)]/platelet count (10.9/L) × 100 [11]

Abdominal ultrasound

- Abdominal ultrasonography was done at baseline and 3 and 12 months after the end of treatment. Liver size, echogenicity, surface of the liver, portal vein diameter, intrahepatic venous and biliary channels, splenic size, and ascites were reported and followed up.

Share wave elastography (SWE)

Assessment of liver stiffness by SWE was done with the Philips iU 22 ultrasonic apparatus (Bothell, WA, Elast PQ). After fasting for 3 h, the patients were examined in a supine position with a fully abducted right arm. The right lobe of the liver is examined through the intercostal spaces. Expression of liver stiffness was done in kilopascals (kPsc) according to the usual standard procedure. We used the following cutoff values for defining fibrosis stages: F ≥ 1, > 7.1 kPa; F ≥ 2, > 7.8 kPa; F ≥ 3, > 8 kPa; and F = 4, > 11.5 kPa [12].

Portal hemodynamics (Doppler ultrasound)

In quiet respiration, the diameter of the portal vein was measured at the hepatic hilum just before branching into right and left. The two cursors were put in the internal wall of the portal vein, excluding the wall [13].

The B-mode gray scale was used to measure the portal vein diameter and cross-sectional area by scanning perpendicular to the long axis of the portal vein. Measurement was done midway between the confluence of the splenic and superior mesenteric vein, and bifurcation of the portal vein during quiet inspiration [14].

The portal vein velocities measured were the time average mean velocity. The software package of the ultrasound machine calculated TAMV electronically. PVV is measured by scanning the extrahepatic portal vein along its longitudinal axis [14].

The portal vein cross-sectional area and PVV were measured 3 times to reduce intra-observer variability, and the mean value was considered. The following formula was used to calculate the portal vein cross-sectional area:

Cross-sectional area \(= \frac{\left(\mathrm{A }\times \mathrm{B}\right) \times 3.14159}{4}\)

A is the longitudinal axis of the portal vein, B is the axial axis of the portal vein, and π = 3.14159 [15].

The resistive index (RI) is the ratio of the upstroke of the systolic wave in the hepatic artery to the end-diastolic flow rate, and normal RI should be 0.6 to 0.9 [16].

The “congestion index” is the ratio between the cross-sectional area (cm2) and the PVV (cm/s) [15].

Treatment of HCV

All patients were given sofosbuvir (400 mg) and daclatasvir (60 mg) daily with or without ribavirin (weight-based) as a dual or triple therapy for 12 or 24 weeks, respectively, according to the guidelines of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) [17].

Statistical analysis

We used the SPSS version 26 for Windows (SPSS Inc., Chicago, Illinois, USA). Quantitative data were presented as mean, SD, and ranges if their distribution was found to be parametric. Qualitative data were presented as numbers and percentages. To compare between two independent groups with qualitative data, χ2 test and/or Fisher’s exact test were used. Independent t test was used to compare two independent groups with quantitative data and parametric distribution. Repeated measures ANOVA is used when comparing more than two paired groups with quantitative data and parametric distribution. Pearson correlation was used to determine the correlation between non-invasive assessment of liver fibrosis and Doppler ultrasound findings. All statistical analyses were significant at a 0.05 level of probability (P ≤ 0.05).

Results

Table 1 shows the baseline data of the studied patients. Most of our patients were males (65%) with a mean age of 60.9 ± 8.81 years. Smoking was reported in 57 (57%) patients, and the comorbidities found were diabetes mellitus 25 (25%) and hypertension 27 (27%). Most patients (89%) received SOF\DAC\RBV for 12 weeks, and only (11%) received SOF\DAC for 24 weeks due to low hemoglobin levels at a baseline of less than 10.5 g/dl (according to The Egyptian National Committee for Control of Viral Hepatitis). Regarding patients who underwent upper endoscopy, esophageal varices were found in 13 patients and portal hypertensive gastropathy “PHG” in 2 patients, while upper endoscopy was normal in 11 patients. The remaining patients refused to undergo upper endoscopy.

Table 1 Baseline clinical data of our patients
Full size table

Table 2 shows the laboratory and ultrasound data of our patients before treatment and 3 and 12 months after the end of treatment. The most significant changes observed were in AFP, AST, ALT, serum albumin, and INR. Other laboratory parameters did not show significant changes. The mean values of AFP, AST, ALT, and INR were significantly decreased 3 and 12 months after the end of treatment compared to baseline. Also, the mean values of these parameters were significantly decreased 12 months after the end of treatment compared to 3 months after the end of treatment. The mean value of serum albumin increased with moderate significance 12 months after the end of treatment compared to the baseline. All patients had criteria for liver cirrhosis. Splenomegaly was detected in 31% of cases. Nine patients (9%) had ascites before treatment. Three months after the end of treatment 13 patients had ascites (4 patients developed new onset ascites), while 12 months after the end of treatment only one patient had ascites. Only two cases developed hepatic focal lesions (diagnosed as hepatocellular carcinoma) 12 months after the end of treatment.

Table 2 Laboratory and ultrasound data of our patients before treatment and 3 and 12 months after the end of treatment
Full size table

Table 3 shows the non-invasive biomarkers of liver fibrosis at baseline and follow-up. There was a significant decrease in all parameters used for the assessment of hepatic fibrosis. Regarding the FIB4 score, the mean score decreased from 3.93 at baseline to 3.28 3 months after treatment (19.81% decrease percentage) and then 2.89 12 months after treatment (26.46% decrease percentage) (P < 0.01). The degree of liver fibrosis measures by SWE showed also a significant decrease; the mean of baseline measurements was 19.8 kPa, while it was 15.88 kPa 3 months after treatment (19.79% decrease percentage) and it was 13.77 kPa 12 months after treatment (30.45% decrease percentage). The APRI also showed a statistically significant reduction. The mean score before therapy was 1.46, while 3 months after treatment, it was 1.13 (22.6% reduction), and 12 months after treatment, it was 0.86 (41.09% reduction) (P < 0.001). The number of patients who had stage F4 fibrosis decreased from 100 patients at baseline to 92 patients 12 months after the end of treatment. The remaining 8 patients showed improvement of their fibrosis stage (became F3).

Table 3 Non-invasive biomarkers of liver fibrosis at baseline and follow-up
Full size table

Table 4 shows the Child–Pugh score, Child class, and MELD score of the studied patients before and after treatment. Significant improvement in Child–Pugh scores was observed. The number of patients in Child class-A increased from 79 at baseline to 90 and 94 patients 3 and 12 months after the end of treatment, respectively. The number of patients in Child class-B decreased from 21 patients before treatment to 7 and 5 patients 3 and 12 months after the end of treatment, respectively. At baseline, there were no Child class-C patients, but 3 patients became decompensated and their Child score was Child-C 3 months after the end of treatment; two of them showed improvement after 12 months of treatment and their Child score improved (became B) while the last patient did not show improvement at the end of our study period. No significant change in MELD score was observed in the present study (P = 0.43).

Table 4 Follow-up in Child–Pugh score and Child class and MELD score in the study group
Full size table

Table 5 shows the changes in Doppler ultrasound of the portal vein and hepatic artery before and after treatment. There was a significant increase in portal vein flow velocity at follow-up (12 months after the end of treatment). There was also a significant decrease in TAMV 3 and 12 months after the end of treatment. There was a significant decrease in the cross-section area 12 months after the end of treatment. Regarding the hepatic arterial resistive index, no significant changes were observed during the follow-up period.

Table 5 Doppler ultrasound studies of the portal vein and hepatic artery before and after treatment
Full size table

Table 6 shows the relation between Doppler ultrasound findings and upper endoscopy in the study group at baseline (n = 26).

Table 6 The relation between Doppler ultrasound findings and upper endoscopy in the study group at baseline
Full size table

The mean value of portal vein blood flow velocity was significantly lower in cases with varices and PHG (P < 0.05) when compared to cases with normal findings. However, the mean value of portal vein diameter was significantly higher in cases with varices and PHG (P < 0.02). The mean value of TAMV was significantly lower in cases with varices and PHG compared to cases with normal findings (P < 0.001).

Table 7 shows the correlations between noninvasive biomarkers of liver fibrosis with Doppler findings in the study group 12 months after the end of treatment. There were positive correlations between noninvasive biomarkers and portal vein flow velocity, portal vein diameter, TAMV, and cross-section area in Doppler in the study group (P < 0.05).

Table 7 Correlation between noninvasive biomarkers of liver fibrosis with Doppler findings in the study group 12 months after the end of treatment
Full size table

Discussion

There is relative paucity in the literature about the effects of direct-acting antiviral drugs on liver fibrosis, portal hemodynamics, and clinical outcomes in cirrhotic patients who received these drugs for chronic HCV. This study was designed to evaluate these changes in the hepatic fibrosis degree, portal hemodynamics, and clinical outcomes in patients with liver cirrhosis after achieving SVR. To our knowledge, this study is one of the few studies to combine clinical, laboratory, imaging, and endoscopic modalities to evaluate the effect of DAAs on the cirrhotic liver.

The results of our study showed that there was a decrease in the levels of liver enzymes (AST and ALT) and an increase in serum albumin level from baseline level to 3 and 12 months after the end of treatment. This is consistent with the study of Hablass et al. who reported a reduction of liver enzymes and serum bilirubin, an increase in serum albumin, and an improvement in INR after achieving SVR with DAAs [18]. Reddy et al. [19] also concluded that DAAs improved liver functions during a short-term follow-up specifically an increase in serum albumin. The same results were concluded in a short‐term follow-up in many other studies [20, 21].

In our study, we found a significant reduction in the degrees of fibrosis after treatment measured by SWE, FIB-4 score, and APRI index in almost all patients. This agrees with Fouad et al. study [22] who found a significant reduction of liver stiffness after 12 weeks of the end of DAA therapy. Elsharkawy et al. in their study [23] reported a 22% improvement in the fibrosis degrees in all fibrosis stages using FibroScan. They also found 81.5% and 93% reductions in FIB4 and APRI scores, respectively. Similarly, our results indicated that the APRI index and FIB-4 score decreased gradually after achieving SVR. This suggests that eradication of HCV may lead to a decrease in the degree of fibrosis and hence the APRI and FIB-4 scores. This reduction is due to a reduction of liver enzymes after treatment that we noticed in our study. Laursen et al. [24] investigated the effects of DAA therapy on hepatic inflammation and fibrosis. They used plasma sCD163 and sMR levels (ELISA) for the assessment of inflammation, transient elastography for the measurement of liver stiffness and galactose elimination capacity for the assessment of liver function. They found a significant reduction in transient elastography readings by about 20% at the end of treatment with early reduction of liver inflammation evidenced by reduction of serum liver enzymes twelve weeks after the end of treatment.

From these data, the improvement in the degree of fibrosis using these noninvasive measures can be attributed to reduced liver enzymes (inflammation) and/or due to real decrease in fibrosis severity. The marked reduction of the APRI and FIB4 scores may be impacted by the marked improvement of the liver enzymes which is agreed upon by Fouad et al. [22].

In our study, Child–Pugh score improved significantly, 12 months after the end of treatment. Child A was (79%) before treatment and became (94%) 12 months after the end of treatment. Child B patients were (21%) before treatment and became (5%) after treatment. There were no Child C cases before treatment. Only one patient decompensated and became Child C 12 months after the end of treatment with a highly statistically significant difference. This improvement is due to improvement in INR, S. Albumin, and S. Bilirubin. In their study, Ali et al. [25] reported improvement in liver functions (ALT, AST, bilirubin, prothrombin time, and INR, with significant elevation of serum albumin) in HCV patients who achieved SVR compared to those who failed to achieve SVR. The Child score however was not found to improve in these patients. In other previous studies, there were variable degrees of improvement in Child scores from 64 to 87% in Child class-B and class-C cirrhosis [26, 27].

Regarding the MELD score, our results showed a non-significant difference in the MELD score between baseline and 12 months after the end of treatment. Berge et al. [28] found also the same results. This may be explained by the fact that only patients with lower MELD scores are candidates for treatment and those with higher scores are not candidates. In contrast, some other authors [26, 27] found variable degrees of improvement in MELD scores from 50 to 83%. This may be due to the treatment of patients with decompensated liver disease with higher MELD and Child score that shows more considerable and significant changes after treatment.

In our study, we found significant improvement in Doppler ultrasound parameters (portal vein blood flow velocity and time average mean velocity) after treatment. Also, there was an improvement in portal vein diameter and cross-section area 12 months after the end of treatment. This change is due to a decrease in fibrosis and its impact on portal hypertension post-treatment with DAAs. This agrees with Hassnine et al. [29] who used portal vein Doppler findings, as indicators for portal hypertension, after achieving SVR.

The reduction in the SWE readings and the improvement in Doppler ultrasound parameters together with the reduction in Fib-4 score and APRI in our study confirms that there is a reduction in the degree of fibrosis and not only due to a reduction of liver enzymes.

In the present study, there was no correlation between Doppler parameters and non-invasive biomarkers at baseline (before treatment), but there was a positive correlation between Doppler parameters with noninvasive biomarkers 12 months after the end of treatment. This agrees with Elwan et al.’s study [30] who found that Fibroscan parameters in moderate fibrosis were positively correlated with Doppler parameters (P < 0.001).

In our study, two patients developed HCC 12 months after the end of treatment (2%), and our findings matched with Nappi et al.’s [31] who reported the occurrence of HCC in 6 out of 241 patients achieved SVR (2.3%). The mean interval before the diagnosis of HCC was 18.5 months after the end of treatment. All patients who developed de novo HCC had F4 fibrosis before treatment of HCV. In his study, all HCC cases were among those who were treated with a SOF-based regimen. Despite being F4, none of the patients who failed to achieve SVR developed HCC.

The higher the success rate of DAAs in achieving SVR, the fewer the side effects, and the positive impact of these agents in improving the degree of fibrosis, with its clinical impact in improving the clinical and laboratory parameters; all these advantages make DAAs as an ideal treatment especially in early stages of chronic HCV-related liver disease [27, 32].

Conclusion

DAAs are safe and effective in the treatment of HCV infection even in the presence of liver cirrhosis. DAAs use leads to viral eradication, improvement of liver functions, improvement in noninvasive markers of fibrosis and Child–Pugh score and class. Significant improvement in the mean value of liver fibrosis (assessed by noninvasive biomarkers, FIB4, liver stiffness, APRI) was observed at 3 and 12 months after the end of treatment.

Limitations

The relatively short period of follow-up is one of the limitations of our study. The improvement of fibrosis may need a longer time to be more evident. The relatively small sample size is another limitation.

Availability of data and materials

All datasets on which the conclusions of the manuscript rely are presented in the main paper.

Abbreviations

SWE:

Shear wave elastography

DAA:

Direct-acting agents

HCC:

Hepatocellular carcinoma

SVR:

Sustained virological response

CHC:

Chronic hepatitis C infection

TAMV:

Time average mean velocity

PVV:

Portal vein flow velocity

References

  1. Han R, Zhou J, François C et al (2019) Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC Infect Dis 19(1):655. https://doi.org/10.1186/s12879-019-4284-9. PMID: 31337339; PMCID: PMC6647266.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. World Health Organization. (2022) Fact sheet. Available online: https://www.who.int/news-room/fact-sheets/detail/ hepatitis-c.

  3. Roche B, Coilly A, Duclos-Vallee et al (2018) The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int 38(Suppl 1):139–145. https://doi.org/10.1111/liv.13659

    Article  PubMed  Google Scholar 

  4. Scaglione V, Mazzitelli M, Costa C et al (2020) Virological and clinical outcome of DAA containing regimens in a cohort of patients in Calabria Region (Southern Italy). Medicina (Kaunas) 56(3):101. https://doi.org/10.3390/medicina56030101

    Article  PubMed  Google Scholar 

  5. European Association for the Study of the Liver (2020) EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol 73(5):1170–1218. https://doi.org/10.1016/j.jhep.2020.08.018

    Article  Google Scholar 

  6. Yoo HW, Park, (2022) Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents. Sci Rep 12(1):193. https://doi.org/10.1038/s41598-021-03272-1

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Hassanin T, Ibraheem H, Makhlouf M et al (2022) Non-invasive evaluation of liver fibrosis changes in patients with chronic hepatitis C after directly acting antiviral drugs. Afro-Egyptian Journal of Infectious and Endemic Diseases 12(1):92–98. https://doi.org/10.21608/aeji.2022.108490.1194

    Article  Google Scholar 

  8. Elsharkawy A, Samir R, El-Kassas M (2022) Fibrosis regression following hepatitis C antiviral therapy. World J Hepatol 14(6):1120–1130. https://doi.org/10.4254/wjh.v14.i6.1120

    Article  PubMed Central  PubMed  Google Scholar 

  9. Poster Session 2: advances in imaging and noninvasive markers of fibrosis; Bile Acids, Cholangiocyte Biology, and Experimental Cholestasis. 2015;62:594A-624A. https://doi.org/10.1002/hep.28218.

  10. Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, MD) 43(6):1317–1325. https://doi.org/10.1002/hep.21178

    Article  CAS  PubMed  Google Scholar 

  11. Wai CT, Greenson JK, Fontana RJ et al (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (Baltimore, MD) 38(2):518–526. https://doi.org/10.1053/jhep.2003.50346

    Article  PubMed  Google Scholar 

  12. Sporea I, Bota S, Gradinaru-Taşcău O et al (2014) Which are the cut-off values of 2D-shear wave elastography (2D-SWE) liver stiffness measurements predicting different stages of liver fibrosis, considering transient elastography (TE) as the reference method? Eur J Radiol 83(3):e118–e122. https://doi.org/10.1016/j.ejrad.2013.12.011

    Article  PubMed  Google Scholar 

  13. Geleto G, Getnet W, Tewelde T (2016) Mean normal portal vein diameter using sonography among clients coming to Radiology Department of Jimma University Hospital, Southwest Ethiopia. Ethiop J Health Sci 26(3):237–242. https://doi.org/10.4314/ejhs.v26i3.6

    Article  PubMed Central  PubMed  Google Scholar 

  14. Ibinaiye PO, Aiyekomogbon JO, Tabari MA, Chom ND, Hamidu AU, Yusuf R (2015) Determination of normal portal vein parameters on triplex ultrasound scan among adults in Zaria, Nigeria. Sub-Saharan Afr J Med 2:33–38

    Article  Google Scholar 

  15. Moriyasu F, Nishida O, Ban N et al (1986) “Congestion index” of the portal vein. AJR Am J Roentgenol 146(4):735–739. https://doi.org/10.2214/ajr.146.4.735

    Article  CAS  PubMed  Google Scholar 

  16. Caiado AH, Blasbalg R, Marcelino AS et al (2007) Complications of liver transplantation: multimodality imaging approach. Radiographics 27(5):1401–1417. https://doi.org/10.1148/rg.275065129

    Article  PubMed  Google Scholar 

  17. El-Akel W, El-Sayed MH, El Kassas M et al (2017) National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepatitis 24(4):262–267. https://doi.org/10.1111/jvh.12668

    Article  CAS  Google Scholar 

  18. Hablass FH, Lashen SA, Mohamed EA (2021) Liver fibrosis regression after direct-acting antivirals for hepatitis C virus: a prospective study. J Gastroenterol Hepatol Res 10(1):3429–3434

    CAS  Google Scholar 

  19. Reddy KR, Lim JK, Kuo A et al (2017) All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther 45(1):115–126. https://doi.org/10.1111/apt.13823

    Article  CAS  PubMed  Google Scholar 

  20. Jacobson IM, Poordad F, Firpi-Morell R et al (2019) Elbasvir/grazoprevir in people with hepatitis C genotype 1 infection and Child-Pugh class B cirrhosis: the C-SALT study. Clin Transl Gastroenterol 10(4):e00007. https://doi.org/10.14309/ctg.0000000000000007

    Article  PubMed Central  PubMed  Google Scholar 

  21. Agwa RH, Elgazzar MH, El-Zayyadi IA et al (2022) Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection. Egypt J Intern Med 34:18. https://doi.org/10.1186/s43162-022-00111-1

    Article  Google Scholar 

  22. Fouad R, Elsharkawy A, Abdel Alem S et al (2019) Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. Eur J Gastroenterol Hepatol 31(9):1129–1134. https://doi.org/10.1097/MEG.0000000000001400

    Article  CAS  PubMed  Google Scholar 

  23. Elsharkawy A, Eletreby R, Fouad R et al (2017) Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Rev Gastroenterol Hepatol 11(8):773–778. https://doi.org/10.1080/17474124.2017.1326816

    Article  CAS  PubMed  Google Scholar 

  24. Laursen TL, Siggaard CB, Kazankov K et al (2020) Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. J Viral Hepatitis 27(1):28–35. https://doi.org/10.1111/jvh.13204

    Article  CAS  Google Scholar 

  25. Nada A, Ata L, Amer A et al (2022) Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients. Med J Viral Hepatitis 7.1(1):21–32. https://doi.org/10.21608/mjvh.2022.279334

    Article  Google Scholar 

  26. Charlton M, Everson GT, Flamm SL et al (2015) Ledipasvir and Sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149(3):649–659. https://doi.org/10.1053/j.gastro.2015.05.010

    Article  CAS  PubMed  Google Scholar 

  27. Manns M, Samuel D, Gane EJ et al (2016) Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16(6):685–697. https://doi.org/10.1016/S1473-3099(16)00052-9

    Article  CAS  PubMed  Google Scholar 

  28. Berge E, Ana A, Elena O et al (2017) Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis. Hepatoma Res 3:209–214. https://doi.org/10.20517/2394-5079.2017.28

    Article  Google Scholar 

  29. Hassnine A, Soliman W, Elsayed A et al (2022) Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV. Egypt Liver J 12:17. https://doi.org/10.1186/s43066-022-00181-4

    Article  Google Scholar 

  30. Elwan N, Hemisa M, Soliman H et al (2021) Doppler ultrasound and fibroscan parameters versus liver biopsy in evaluation of hepatic fibrosis in Egyptian patients with chronic hepatitis C. Afro-Egypt J Infect Endem Dis 11(2):186–198. https://doi.org/10.21608/aeji.2021.55780.1127

    Article  Google Scholar 

  31. Nappi A, Perrella A, Rinaldi L et al (2019) Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up? Eur J Hosp Pharm 26(4):243–244. https://doi.org/10.1136/ejhpharm-2019-001975

    Article  PubMed Central  PubMed  Google Scholar 

  32. Wu DB, Jiang W, Wang YH et al (2019) Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: real-world experience of a retrospective study. J Viral Hepatitis 26(3):316–322. https://doi.org/10.1111/jvh.13033

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

We did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit organizations.

Author information

Authors and Affiliations

  1. Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt

    Waleed Attia Hassan, Sherif I. Kamel, Ibrahim Abdel Naby Mahmoud, Nahed Makhlouf & Sahar M. Hassany

  2. Department of Diagnostic Radiology, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt

    Mahmoud Moubark

Authors
  1. Waleed Attia Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sherif I. Kamel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ibrahim Abdel Naby Mahmoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nahed Makhlouf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahmoud Moubark
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sahar M. Hassany
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

WAH participated in the design of the study and coordination of the work and drafted the manuscript. SIK participated in the design of the study, revised the statistical analysis, and helped in drafting the manuscript. IAM participated in the design of the study, curation of patients, and data entry. NM performed the statistical analysis and helped in drafting the manuscript. MM participated in the study design and performed the Doppler study. SMH participated in the design of the study and performed share wave elastography. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Waleed Attia Hassan.

Ethics declarations

Ethics approval and consent to participate

The study protocol was registered at ClinicalTrials.gov ID: NCT03241823. Our study was approved by the Medical Ethics Committee of the Institutional Review Board of the Faculty of Medicine, Assiut University, Egypt.

Consent for publication

We obtained written consent from all participants according to the Declaration of Helsinki.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hassan, W.A., Kamel, S.I., Mahmoud, I.A.N. et al. Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs). Egypt Liver Journal 13, 49 (2023). https://doi.org/10.1186/s43066-023-00284-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43066-023-00284-6

Keywords